The safety of gadolinium-based contrast agents for MRI continues to generate much controversy and discussion. As both a radiologist and a lawyer, Dr. Alexander Radbruch, JD, is well-placed to comment on the most significant recent developments in gadolinium retention in the brain, how best to use these agents, and how radiologists and manufacturers can help to avoid being sued.
The description & caption for this interview to be published online on 01.03.2019 will Philipp Ward sent directly.Video from ECR 2019: Alexander Radbruch on gadolinium debate
Feb 28, 2019
Latest in Conference
Fujifilm to collaborate with Amazon at ECR 2026
February 13, 2026
AGFA HealthCare to highlight platform advances at ECR 2026
January 29, 2026
Bayer to emphasize phase III clinical trial data at ECR 2026
January 29, 2026
ECR 2026 achieves record number of abstract submissions
January 13, 2026


















